Free Trial

Veradigm (MDRX) Competitors

Veradigm logo
$4.70 +0.49 (+11.64%)
As of 03:49 PM Eastern

MDRX vs. OMCL, HSTM, CRTX, CNGL, OMQS, KBNT, BLIV, SAIC, NN, and MAN

Should you be buying Veradigm stock or one of its competitors? The main competitors of Veradigm include Omnicell (OMCL), HealthStream (HSTM), Cortexyme (CRTX), Canna-Global Acquisition (CNGL), OMNIQ (OMQS), Kubient (KBNT), Belive (BLIV), Science Applications International (SAIC), NextNav (NN), and ManpowerGroup (MAN).

Veradigm vs. Its Competitors

Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Omnicell has lower revenue, but higher earnings than Veradigm.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veradigm$1.53B0.33N/AN/AN/A
Omnicell$1.11B1.26$12.53M$0.4665.09

Omnicell has a net margin of 1.87% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.60% beat Veradigm's return on equity.

Company Net Margins Return on Equity Return on Assets
VeradigmN/A N/A N/A
Omnicell 1.87%4.60%2.56%

In the previous week, Veradigm had 3 more articles in the media than Omnicell. MarketBeat recorded 3 mentions for Veradigm and 0 mentions for Omnicell. Omnicell's average media sentiment score of 1.88 beat Veradigm's score of 0.40 indicating that Omnicell is being referred to more favorably in the news media.

Company Overall Sentiment
Veradigm Neutral
Omnicell Very Positive

97.7% of Omnicell shares are owned by institutional investors. 2.3% of Veradigm shares are owned by insiders. Comparatively, 2.5% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Veradigm has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Veradigm presently has a consensus target price of $13.00, suggesting a potential upside of 176.60%. Omnicell has a consensus target price of $44.83, suggesting a potential upside of 49.74%. Given Veradigm's higher possible upside, research analysts plainly believe Veradigm is more favorable than Omnicell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veradigm
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Omnicell
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

Omnicell beats Veradigm on 9 of the 13 factors compared between the two stocks.

Get Veradigm News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDRX and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDRX vs. The Competition

MetricVeradigmComputer integrated systems design IndustryBusiness SectorNASDAQ Exchange
Market Cap$508.85M$1.20B$13.04B$8.96B
Dividend YieldN/A2.62%2.70%4.02%
P/E RatioN/A2.1828.8620.15
Price / Sales0.330.3639.72127.85
Price / CashN/A9.4426.3757.97
Price / BookN/A3.396.215.62
Net IncomeN/A$223.79M$188.52M$248.50M
7 Day Performance-3.09%-0.57%1.79%5.54%
1 Month Performance6.82%1.13%2.79%7.52%
1 Year Performance-51.30%-4.43%39.51%22.06%

Veradigm Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDRX
Veradigm
2.9717 of 5 stars
$4.70
+11.6%
$13.00
+176.6%
-56.4%$508.85M$1.53B0.008,000Gap Up
OMCL
Omnicell
2.7618 of 5 stars
$29.40
+0.1%
$44.83
+52.5%
+12.8%$1.38B$1.11B63.913,670Positive News
HSTM
HealthStream
4.3128 of 5 stars
$27.67
+0.4%
$31.50
+13.8%
-1.2%$840.97M$291.65M43.921,093
CRTX
Cortexyme
N/A$1.55
+3.3%
N/A+126.4%$46.73MN/A-0.5255News Coverage
CNGL
Canna-Global Acquisition
N/A$10.74
flat
N/AN/A$70.99MN/A0.002
OMQS
OMNIQ
N/A$0.06
+1.0%
N/A-83.1%$642K$81.19M-0.02190Gap Up
KBNT
Kubient
N/AN/AN/AN/A$1K$1.17M0.0040
BLIV
Belive
N/A$3.16
-11.2%
N/AN/A$0.00$1.85M0.0034Positive News
SAIC
Science Applications International
3.7661 of 5 stars
$112.61
+3.1%
$124.73
+10.8%
+2.3%$5.28B$7.51B18.9926,000News Coverage
Dividend Announcement
High Trading Volume
NN
NextNav
1.488 of 5 stars
$15.20
+0.9%
$20.00
+31.6%
+94.8%$2.00B$5.67M-14.9060
MAN
ManpowerGroup
4.8525 of 5 stars
$40.39
-0.2%
$50.60
+25.3%
-37.3%$1.87B$17.85B17.5626,700

Related Companies and Tools


This page (NASDAQ:MDRX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners